Breast cancer metastasis: Issues for the personalization of its prevention and treatment

American Journal of Pathology

Volumn 183, Issue 4, 2013, Pages 1084-1095

  Marino, Natascia ^a   Woditschka, Stephan ^a   Reed, L Tiffany ^a   Nakayama, Joji ^a   Mayer, Musa ^b   Wetzel, Maria ^c   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AdvancedBCorg   (United States)

^c Michigan Breast Cancer Coalition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BEVACIZUMAB; CD24 ANTIGEN; CD44V ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DENOSUMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GEFITINIB; LAPATINIB; LYSOPHOSPHATIDIC ACID RECEPTOR; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAC1 PROTEIN; SORAFENIB; TAMOXIFEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VASCULOTROPIN; VORINOSTAT; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; BONE METASTASIS; BRAIN METASTASIS; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CIRCULATING TUMOR CELL; DNA METHYLATION; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; GENOMIC INSTABILITY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; PATIENT ADVOCACY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84884549440     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.06.012     Document Type: Review

References (108)

1. P.S. Steeg Tumor metastasis: mechanistic insights and clinical challenges Nat Med 12 2006 895 904
2. E. Comen, L. Norton, and J. Massagué Clinical implications of cancer self-seeding Nat Rev Clin Oncol 8 2011 369 377
3. D.R. Welch Do we need to redefine a cancer metastasis and staging definitions? Breast Dis 26 2006 3 12
4. C.A. Klein Parallel progression of primary tumours and metastases Nat Rev Cancer 9 2009 302 312
5. S. Paget The distribution of secondary growths in cancer of the breast. 1889 Cancer Metastasis Rev 8 1989 98 101
6. D.X. Nguyen, P.D. Bos, and J. Massagué Metastasis: from dissemination to organ-specific colonization Nat Rev Cancer 9 2009 274 284
7. A.E. Vernon, S.J. Bakewell, and L.A. Chodosh Deciphering the molecular basis of breast cancer metastasis with mouse models Rev Endocr Metab Disord 8 2007 199 213
8. W. Sun, and J. Yang Functional mechanisms for human tumor suppressors J Cancer 1 2010 136 140
9. P.S. Steeg Metastasis suppressors alter the signal transduction of cancer cells Nat Rev Cancer 3 2003 55 63
10. S.C. Smith, and D. Theodorescu Learning therapeutic lessons from metastasis suppressor proteins Nat Rev Cancer 9 2009 253 264
11. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
12. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors [Erratum appeared in Nat Rev Cancer 2005, 5:580] Nat Rev Cancer 5 2005 341 354
13. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart, and M. Press Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726
14. K.L. Blackwell, H.J. Burstein, A.M. Storniolo, H.S. Rugo, G. Sledge, G. Aktan, C. Ellis, A. Florance, S. Vukelja, J. Bischoff, J. Baselga, and J. O'Shaughnessy Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study J Clin Oncol 30 2012 2585 2592
15. J. Baselga, J. Cortés, S.B. Kim, S.A. Im, R. Hegg, Y.H. Im, L. Roman, J.L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M.C. Benyunes, G. Ross, S.M. Swain CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
16. S. Verma, D. Miles, L. Gianni, I.E. Krop, M. Welslau, J. Baselga, M. Pegram, D.Y. Oh, V. Diéras, E. Guardino, L. Fang, M.W. Lu, S. Olsen, K. Blackwell EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced breast cancer [Erratum appeared in N Engl J Med 2013, 368:2442] N Engl J Med 367 2012 1783 1791
17. D. Palmieri, J.L. Bronder, J.M. Herring, T. Yoneda, R.J. Weil, A.M. Stark, R. Kurek, E. Vega-Valle, L. Feigenbaum, D. Halverson, A.O. Vortmeyer, S.M. Steinberg, K. Aldape, and P.S. Steeg Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain Cancer Res 67 2007 4190 4198
18. S.E. Moody, C.J. Sarkisian, K.T. Hahn, E.J. Gunther, S. Pickup, K.D. Dugan, N. Innocent, R.D. Cardiff, M.D. Schnall, and L.A. Chodosh Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis Cancer Cell 2 2002 451 461
19. P. Khalili, A. Arakelian, G. Chen, G. Singh, and S.A. Rabbani Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer [Erratum appeared in Oncogene 2006, 25:492] Oncogene 24 2005 6657 6666
20. A. Chow, C.L. Arteaga, and S.E. Wang When tumor suppressor TGFbeta meets the HER2 (ERBB2) oncogene J Mammary Gland Biol Neoplasia 16 2011 81 88
21. Y.M. Li, Y. Pan, Y. Wei, X. Cheng, B.P. Zhou, M. Tan, X. Zhou, W. Xia, G.N. Hortobagyi, D. Yu, and M.C. Hung Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis Cancer Cell 6 2004 459 469
22. R.K. Vadlamudi, A.A. Sahin, L. Adam, R.A. Wang, and R. Kumar Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215 FEBS Lett 543 2003 76 80
23. L. Yen, X.L. You, A.E. Al Moustafa, G. Batist, N.E. Hynes, S. Mader, S. Meloche, and M.A. Alaoui-Jamali Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis Oncogene 19 2000 3460 3469
24. G. Niu, and W.B. Carter Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways Cancer Res 67 2007 1487 1493
25. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
26. R.S. Mehta, W.E. Barlow, K.S. Albain, T.A. Vandenberg, S.R. Dakhil, N.R. Tirumali, D.L. Lew, D.F. Hayes, J.R. Gralow, R.B. Livingston, and G.N. Hortobagyi Combination anastrozole and fulvestrant in metastatic breast cancer N Engl J Med 367 2012 435 444
27. J.J. James, A.J. Evans, S.E. Pinder, E. Gutteridge, K.L. Cheung, S. Chan, and J.F. Robertson Bone metastases from breast carcinoma: histopathological- radiological correlations and prognostic features Br J Cancer 89 2003 660 665
28. R.S. Kim, A. Avivar-Valderas, Y. Estrada, P. Bragado, M.S. Sosa, J.A. Aguirre-Ghiso, and J.E. Segall Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer PLoS One 7 2012 e35569
29. A. Hackshaw, M. Roughton, S. Forsyth, K. Monson, K. Reczko, R. Sainsbury, and M. Baum Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer J Clin Oncol 29 2011 1657 1663
30. D. Chakravarty, S.S. Nair, B. Santhamma, B.C. Nair, L. Wang, A. Bandyopadhyay, J.K. Agyin, D. Brann, L.Z. Sun, I.T. Yeh, F.Y. Lee, R.R. Tekmal, R. Kumar, and R.K. Vadlamudi Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells Cancer Res 70 2010 4092 4101
31. S.A. Fuqua, and Y. Cui Targeting the estrogen receptor in clinical breast cancer Breast Dis 15 2002 3 11
32. G.J. Sabnis, D. Jelovac, B. Long, and A. Brodie The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation Cancer Res 65 2005 3903 3910
33. S. Oesterreich, W. Deng, S. Jiang, X. Cui, M. Ivanova, R. Schiff, K. Kang, D.L. Hadsell, J. Behrens, and A.V. Lee Estrogen-mediated down-regulation of E-cadherin in breast cancer cells Cancer Res 63 2003 5203 5208
34. L.V. Rhodes, S.P. Short, N.F. Neel, V.A. Salvo, Y. Zhu, S. Elliott, Y. Wei, D. Yu, M. Sun, S.E. Muir, J.P. Fonseca, M.R. Bratton, C. Segar, S.L. Tilghman, T. Sobolik-Delmaire, L.W. Horton, S. Zaja-Milatovic, B.M. Collins-Burow, S. Wadsworth, B.S. Beckman, C.E. Wood, S.A. Fuqua, K.P. Nephew, P. Dent, R.A. Worthylake, T.J. Curiel, M.C. Hung, A. Richmond, and M.E. Burow Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer Cancer Res 71 2011 603 613
35. A. Di Leo, and L. Malorni Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven J Clin Oncol 30 2012 1897 1900
36. S. Loi, S. Michiels, J. Baselga, J.M. Bartlett, S.K. Singhal, V.S. Sabine, A.H. Sims, T. Sahmoud, J.M. Dixon, M.J. Piccart, and C. Sotiriou PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer PLoS One 8 2013 e53292
37. J.A. Sparano TAILORx: trial assigning individualized options for treatment (Rx) Clin Breast Cancer 7 2006 347 350
38. Y. Kang, P.M. Siegel, W. Shu, M. Drobnjak, S.M. Kakonen, C. Cordón-Cardo, T.A. Guise, and J. Massagué A multigenic program mediating breast cancer metastasis to bone Cancer Cell 3 2003 537 549
39. L.A. Kingsley, P.G. Fournier, J.M. Chirgwin, and T.A. Guise Molecular biology of bone metastasis Mol Cancer Ther 6 2007 2609 2617
40. A.T. Stopeck, A. Lipton, J.J. Body, G.G. Steger, K. Tonkin, R.H. de Boer, M. Lichinitser, Y. Fujiwara, D.A. Yardley, M. Viniegra, M. Fan, Q. Jiang, R. Dansey, S. Jun, and A. Braun Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139
41. K. Jin, L. Teng, Y. Shen, K. He, Z. Xu, and G. Li Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review Clin Transl Oncol 12 2010 473 480
42. N. Niikura, J. Liu, N. Hayashi, E.A. Mittendorf, Y. Gong, S.L. Palla, Y. Tokuda, A.M. Gonzalez-Angulo, G.N. Hortobagyi, and N.T. Ueno Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors J Clin Oncol 30 2012 593 599
43. L.S. Lindström, E. Karlsson, U.M. Wilking, U. Johansson, J. Hartman, E.K. Lidbrink, T. Hatschek, L. Skoog, and J. Bergh Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 2012 2601 2608
44. E. Amir, M. Clemons, C.A. Purdie, N. Miller, P. Quinlan, W. Geddie, R.E. Coleman, O.C. Freedman, L.B. Jordan, and A.M. Thompson Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies Cancer Treat Rev 38 2012 708 714
45. G. Curigliano, V. Bagnardi, G. Viale, L. Fumagalli, N. Rotmensz, G. Aurilio, M. Locatelli, G. Pruneri, S. Giudici, M. Bellomi, P. Della Vigna, L. Monfardini, F. Orsi, F. Nole, E. Munzone, and A. Goldhirsch Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 22 2011 2227 2233
46. A. Akcakanat, A. Sahin, A.N. Shaye, M.A. Velasco, and F. Meric-Bernstam Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases Cancer 112 2008 2352 2358
47. J.M. Wu, M.J. Fackler, M.K. Halushka, D.W. Molavi, M.E. Taylor, W.W. Teo, C. Griffin, J. Fetting, N.E. Davidson, A.M. De Marzo, J.L. Hicks, D. Chitale, M. Ladanyi, S. Sukumar, and P. Argani Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 2008 1938 1946
48. J. Mehrotra, M. Vali, M. McVeigh, S.L. Kominsky, M.J. Fackler, J. Lahti-Domenici, K. Polyak, N. Sacchi, E. Garrett-Mayer, P. Argani, and S. Sukumar Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung Clin Cancer Res 10 2004 3104 3109
49. C. Lo Nigro, D. Vivenza, M. Monteverde, L. Lattanzio, O. Gojis, O. Garrone, A. Comino, M. Merlano, P.R. Quinlan, N. Syed, C.A. Purdie, A. Thompson, C. Palmieri, and T. Crook High frequency of complex TP53 mutations in CNS metastases from breast cancer Br J Cancer 106 2012 397 404
50. A.D. Singhi, A. Cimino-Mathews, R.B. Jenkins, F. Lan, S.R. Fink, H. Nassar, R. Vang, J.H. Fetting, J. Hicks, S. Sukumar, A.M. De Marzo, and P. Argani MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors Mod Pathol 25 2012 378 387
51. H. Wikman, K. Lamszus, N. Detels, L. Uslar, M. Wrage, C. Benner, I. Hohensee, B. Ylstra, K. Eylmann, M. Zapatka, G. Sauter, D. Kemming, M. Glatzel, V. Müller, M. Westphal, and K. Pantel Relevance of PTEN loss in brain metastasis formation in breast cancer patients Breast Cancer Res 14 2012 R49
52. L. Ding, M.J. Ellis, S. Li, D.E. Larson, K. Chen, and J.W. Wallis Genome remodelling in a basal-like breast cancer metastasis and xenograft Nature 464 2010 999 1005
53. S.P. Shah, R.D. Morin, J. Khattra, L. Prentice, T. Pugh, A. Burleigh, A. Delaney, K. Gelmon, R. Guliany, J. Senz, C. Steidl, R.A. Holt, S. Jones, M. Sun, G. Leung, R. Moore, T. Severson, G.A. Taylor, A.E. Teschendorff, K. Tse, G. Turashvili, R. Varhol, R.L. Warren, P. Watson, Y. Zhao, C. Caldas, D. Huntsman, M. Hirst, M.A. Marra, and S. Aparicio Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution Nature 461 2009 809 813
54. S. Nik-Zainal, P. Van Loo, D.C. Wedge, L.B. Alexandrov, C.D. Greenman, K.W. Lau Breast Cancer Working Group of the International Cancer Genome Consortium The life history of 21 breast cancers Cell 149 2012 994 1007
55. N. Navin, A. Krasnitz, L. Rodgers, K. Cook, J. Meth, J. Kendall, M. Riggs, Y. Eberling, J. Troge, V. Grubor, D. Levy, P. Lundin, S. Maner, A. Zetterberg, J. Hicks, and M. Wigler Inferring tumor progression from genomic heterogeneity Genome Res 20 2010 68 80
56. P.J. Stephens, D.J. McBride, M.L. Lin, I. Varela, E.D. Pleasance, J.T. Simpson, L.A. Stebbings, C. Leroy, S. Edkins, L.J. Mudie, C.D. Greenman, M. Jia, C. Latimer, J.W. Teague, K.W. Lau, J. Burton, M.A. Quail, H. Swerdlow, C. Churcher, R. Natrajan, A.M. Sieuwerts, J.W. Martens, D.P. Silver, A. Langerød, H.E. Russnes, J.A. Foekens, J.S. Reis-Filho, L. van 't Veer, A.L. Richardson, A.L. Børresen-Dale, P.J. Campbell, P.A. Futreal, and M.R. Stratton Complex landscapes of somatic rearrangement in human breast cancer genomes Nature 462 2009 1005 1010
57. S. Banerji, K. Cibulskis, C. Rangel-Escareno, K.K. Brown, S.L. Carter, and A.M. Frederick Sequence analysis of mutations and translocations across breast cancer subtypes Nature 486 2012 405 409
58. J. Li, A.C. Karaplis, D.C. Huang, P.M. Siegel, A. Camirand, X.F. Yang, W.J. Muller, and R. Kremer PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target J Clin Invest 121 2011 4655 4669
59. A.J. Minn, G.P. Gupta, P.M. Siegel, P.D. Bos, W. Shu, D.D. Giri, A. Viale, A.B. Olshen, W.L. Gerald, and J. Massagué Genes that mediate breast cancer metastasis to lung Nature 436 2005 518 524
60. G. Vlastos, D.L. Smith, S.E. Singletary, N.Q. Mirza, T.M. Tuttle, R.J. Popat, S.A. Curley, L.M. Ellis, M.S. Roh, and J.N. Vauthey Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases Ann Surg Oncol 11 2004 869 874
61. B. Gril, D. Palmieri, J.L. Bronder, J.M. Herring, E. Vega-Valle, L. Feigenbaum, D.J. Liewehr, S.M. Steinberg, M.J. Merino, S.D. Rubin, and P.S. Steeg Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain J Natl Cancer Inst 100 2008 1092 1103
62. T. Bachelot, G. Romieu, M. Campone, V. Diéras, C. Cropet, F. Dalenc, M. Jimenez, E. Le Rhun, J.Y. Pierga, A. Gonçalves, M. Leheurteur, J. Domont, M. Gutierrez, H. Curé, J.M. Ferrero, and C. Labbe-Devilliers Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Lancet Oncol 14 2013 64 71
63. A.M. Brufsky, M. Mayer, H.S. Rugo, P.A. Kaufman, E. Tan-Chiu, D. Tripathy, I.C. Tudor, L.I. Wang, M.G. Brammer, M. Shing, M.U. Yood, and D.A. Yardley Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER Clin Cancer Res 17 2011 4834 4843
64. A. Frati, E. Chereau, C. Coutant, C. Bezu, M. Antoine, J. Chopier, E. Daraï, S. Uzan, J. Gligorov, and R. Rouzier Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors Breast Cancer Res Treat 132 2012 601 607
65. B. Gril, D. Palmieri, Y. Qian, D. Smart, L. Ileva, D.J. Liewehr, S.M. Steinberg, and P.S. Steeg Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis Clin Cancer Res 17 2011 142 153
66. Y. Qian, E. Hua, K. Bisht, S. Woditschka, K.W. Skordos, D.J. Liewehr, S.M. Steinberg, E. Brogi, M.M. Akram, J.K. Killian, D.C. Edelman, M. Pineda, S. Scurci, Y.Y. Degenhardt, S. Laquerre, T.A. Lampkin, P.S. Meltzer, K. Camphausen, P.S. Steeg, and D. Palmieri Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain Clin Exp Metastasis 28 2011 899 908
67. D. Palmieri, P.R. Lockman, F.C. Thomas, E. Hua, J. Herring, E. Hargrave, M. Johnson, N. Flores, Y. Qian, E. Vega-Valle, K.S. Taskar, V. Rudraraju, R.K. Mittapalli, J.A. Gaasch, K.A. Bohn, H.R. Thorsheim, D.J. Liewehr, S. Davis, J.F. Reilly, R. Walker, J.L. Bronder, L. Feigenbaum, S.M. Steinberg, K. Camphausen, P.S. Meltzer, V.M. Richon, Q.R. Smith, and P.S. Steeg Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks Clin Cancer Res 15 2009 6148 6157
68. D.P. Fitzgerald, D.L. Emerson, Y. Qian, T. Anwar, D.J. Liewehr, S.M. Steinberg, S. Silberman, D. Palmieri, and P.S. Steeg TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells [Erratum appeared in Mol Cancer Ther 2013, 12:241] Mol Cancer Ther 11 2012 1959 1967
69. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
70. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke Prospective identification of tumorigenic breast cancer cells [Erratum appeared in Proc Natl Acad Sci USA 2003, 100:6890] Proc Natl Acad Sci USA 100 2003 3983 3988
71. A.K. Croker, D. Goodale, J. Chu, C. Postenka, B.D. Hedley, D.A. Hess, and A.L. Allan High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability J Cell Mol Med 13 2009 2236 2252
72. A.F. Chambers, G.N. Naumov, S.A. Vantyghem, and A.B. Tuck Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency Breast Cancer Res 2 2000 400 407
73. X. Li, M.T. Lewis, J. Huang, C. Gutierrez, C.K. Osborne, M.F. Wu, S.G. Hilsenbeck, A. Pavlick, X. Zhang, G.C. Chamness, H. Wong, J. Rosen, and J.C. Chang Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 2008 672 679
74. C.L. Chaffer, I. Brueckmann, C. Scheel, A.J. Kaestli, P.A. Wiggins, L.O. Rodrigues, M. Brooks, F. Reinhardt, Y. Su, K. Polyak, L.M. Arendt, C. Kuperwasser, B. Bierie, and R.A. Weinberg Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state Proc Natl Acad Sci USA 108 2011 7950 7955
75. G.N. Naumov, E. Bender, D. Zurakowski, S.Y. Kang, D. Sampson, E. Flynn, R.S. Watnick, O. Straume, L.A. Akslen, J. Folkman, and N. Almog A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype J Natl Cancer Inst 98 2006 316 325
76. A.F. Chambers, A.C. Groom, and I.C. MacDonald Dissemination and growth of cancer cells in metastatic sites Nat Rev Cancer 2 2002 563 572
77. G.N. Naumov, J.L. Townson, I.C. MacDonald, S.M. Wilson, V.H. Bramwell, A.C. Groom, and A.F. Chambers Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases Breast Cancer Res Treat 82 2003 199 206
78. A.C. Ranganathan, A.P. Adam, L. Zhang, and J.A. Aguirre-Ghiso Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther 5 2006 729 735
79. J.C. Marshall, J.W. Collins, J. Nakayama, C.E. Horak, D.J. Liewehr, S.M. Steinberg, M. Albaugh, F. Vidal-Vanaclocha, D. Palmieri, M. Barbier, M. Murone, and P.S. Steeg Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer J Natl Cancer Inst 104 2012 1306 1319
80. D. Barkan, H. Kleinman, J.L. Simmons, H. Asmussen, A.K. Kamaraju, M.J. Hoenorhoff, Z.Y. Liu, S.V. Costes, E.H. Cho, S. Lockett, C. Khanna, A.F. Chambers, and J.E. Green Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton Cancer Res 68 2008 6241 6250
81. D.E. White, N.A. Kurpios, D. Zuo, J.A. Hassell, S. Blaess, U. Mueller, and W.J. Muller Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction Cancer Cell 6 2004 159 170
82. M.J. Slade, and R.C. Coombes The clinical significance of disseminated tumor cells in breast cancer Nat Clin Pract Oncol 4 2007 30 41
83. M.J. Bissell, and W.C. Hines Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression Nat Med 17 2011 320 329
84. P. Carmeliet, and R.K. Jain Molecular mechanisms and clinical applications of angiogenesis Nature 473 2011 298 307
85. J.M. Ebos, and R.S. Kerbel Antiangiogenic therapy: impact on invasion, disease progression, and metastasis [Erratum appeared in Nat Rev Clin Oncol 2011, 8:221 and in Nat Rev Clin Oncol 2011, 8:316] Nat Rev Clin Oncol 8 2011 210 221
86. S. Hellman, and R.R. Weichselbaum Oligometastases J Clin Oncol 13 1995 8 10
87. Y. Nieto, S. Nawaz, R.B. Jones, E.J. Shpall, P.J. Cagnoni, P.A. McSweeney, A. Barón, C. Razook, S. Matthes, and S.I. Bearman Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer J Clin Oncol 20 2002 707 718
88. M. Knauer, S. Mook, E.J. Rutgers, R.A. Bender, M. Hauptmann, M.J. van de Vijver, R.H. Koornstra, J.M. Bueno-de-Mesquita, S.C. Linn, and L.J. van 't Veer The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer Breast Cancer Res Treat 120 2010 655 661
89. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F.L. Baehner, M.G. Walker, D. Watson, T. Park, W. Hiller, E.R. Fisher, D.L. Wickerham, J. Bryant, and N. Wolmark A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
90. N. Niikura, T. Iwamoto, S. Masuda, N. Kumaki, T. Xiaoyan, M. Shirane, K. Mori, B. Tsuda, T. Okamura, Y. Saito, Y. Suzuki, and Y. Tokuda Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer Cancer Sci 103 2012 1508 1512
91. E. Botteri, D. Disalvatore, G. Curigliano, J. Brollo, V. Bagnardi, G. Viale, F. Orsi, A. Goldhirsch, and N. Rotmensz Biopsy of liver metastasis for women with breast cancer: impact on survival Breast 21 2012 284 288
92. J.B. Smerage, and D.F. Hayes The measurement and therapeutic implications of circulating tumour cells in breast cancer Br J Cancer 94 2006 8 12
93. C. Alix-Panabières, and K. Pantel Circulating tumor cells: liquid biopsy of cancer Clin Chem 59 2013 110 118
94. G. Kallergi, M.A. Papadaki, E. Politaki, D. Mavroudis, V. Georgoulias, and S. Agelaki Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients Breast Cancer Res 13 2011 R59
95. M. Wallwiener, A.D. Hartkopf, I. Baccelli, S. Riethdorf, S. Schott, K. Pantel, F. Marme, C. Sohn, A. Trumpp, B. Rack, B. Aktas, E.F. Solomayer, V. Müller, W. Janni, A. Schneeweiss, and T.N. Fehm The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer Breast Cancer Res Treat 137 2013 503 510
96. S. Riethdorf, H. Fritsche, V. Müller, T. Rau, C. Schindlbeck, B. Rack, W. Janni, C. Coith, K. Beck, F. Janicke, S. Jackson, T. Gornet, M. Cristofanilli, and K. Pantel Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system Clin Cancer Res 13 2007 920 928
97. L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M.R. Somerfield, D.F. Hayes, R.C. Bast Jr. American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 2007 5287 5312
98. A.A. Powell, A.H. Talasaz, H. Zhang, M.A. Coram, A. Reddy, G. Deng, M.L. Telli, R.H. Advani, R.W. Carlson, J.A. Mollick, S. Sheth, A.W. Kurian, J.M. Ford, F.E. Stockdale, S.R. Quake, R.F. Pease, M.N. Mindrinos, G. Bhanot, S.H. Dairkee, R.W. Davis, and S.S. Jeffrey Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines PLoS One 7 2012 e33788
99. M. Pestrin, S. Bessi, F. Galardi, M. Truglia, A. Biggeri, C. Biagioni, S. Cappadona, L. Biganzoli, A. Giannini, and A. Di Leo Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients Breast Cancer Res Treat 118 2009 523 530
100. D. Madhavan, M. Zucknick, M. Wallwiener, K. Cuk, C. Modugno, M. Scharpff, S. Schott, J. Heil, A. Turchinovich, R. Yang, A. Benner, S. Riethdorf, A. Trumpp, C. Sohn, K. Pantel, A. Schneeweiss, and B. Burwinkel Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer Clin Cancer Res 18 2012 5972 5982
101. W.P. Kloosterman, and R.H. Plasterk The diverse functions of microRNAs in animal development and disease Dev Cell 11 2006 441 450
102. K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
103. Y.A. Yang, O. Dukhanina, B. Tang, M. Mamura, J.J. Letterio, J. MacGregor, S.C. Patel, S. Khozin, Z.Y. Liu, J. Green, M.R. Anver, G. Merlino, and L.M. Wakefield Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects J Clin Invest 109 2002 1607 1615
104. P.S. Steeg Perspective: the right trials Nature 485 2012 S58 S59
105. R.B. Sherman, J. Woodcock, J. Norden, C. Grandinetti, and R.J. Temple New FDA regulation to improve safety reporting in clinical trials N Engl J Med 365 2011 3 5
106. P.E. Goss, and A.F. Chambers Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10 2010 871 877
107. F. Andre, S. Delaloge, and J.C. Soria Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 29 2011 1236 1238
108. A.D. Barker, C.C. Sigman, G.J. Kelloff, N.M. Hylton, D.A. Berry, and L.J. Esserman I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clin Pharmacol Ther 86 2009 97 100